- Report
- March 2024
- 185 Pages
Global
From €3253EUR$3,374USD£2,782GBP
€3614EUR$3,749USD£3,091GBP
- Report
- March 2024
- 194 Pages
Global
From €3253EUR$3,374USD£2,782GBP
€3614EUR$3,749USD£3,091GBP
- Report
- March 2024
- 200 Pages
Global
From €4001EUR$4,150USD£3,422GBP
- Report
- March 2024
- 189 Pages
Global
From €3253EUR$3,374USD£2,782GBP
€3614EUR$3,749USD£3,091GBP
- Report
- July 2023
- 145 Pages
Global
From €3037EUR$3,150USD£2,597GBP
- Report
- May 2019
- 96 Pages
Global
From €2892EUR$3,000USD£2,474GBP
- Report
- March 2022
- 120 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- November 2018
- 134 Pages
Global
From €4579EUR$4,750USD£3,917GBP
- Report
- December 2022
Global
€4579EUR$4,750USD£3,917GBP
- Report
- May 2023
- 78 Pages
Global
From €3500EUR$3,889USD£3,098GBP
The Automated Breast Ultrasound System (ABUS) is a technology used in women's health to detect breast cancer. It is a non-invasive imaging technique that uses sound waves to create a three-dimensional image of the breast. This technology is used to supplement traditional mammography, which is the gold standard for breast cancer screening. ABUS is particularly useful for women with dense breast tissue, as it can detect smaller lesions that may be missed by mammography. It is also beneficial for women who are at high risk for breast cancer, as it can detect cancer at an earlier stage.
The ABUS market is growing rapidly, driven by increasing awareness of the importance of early detection of breast cancer and the need for improved screening methods. The market is expected to continue to grow in the coming years, driven by technological advancements and increasing demand for improved breast cancer screening.
Some of the major companies in the ABUS market include GE Healthcare, Siemens Healthineers, Hologic, FUJIFILM SonoSite, and Philips Healthcare. Show Less Read more